Wall Street analysts expect Fennec Pharmaceuticals Inc (NASDAQ:FENC) to post earnings of ($0.15) per share for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Fennec Pharmaceuticals’ earnings. Fennec Pharmaceuticals posted earnings per share of ($0.14) during the same quarter last year, which would indicate a negative year over year growth rate of 7.1%. The business is expected to issue its next quarterly earnings results on Monday, August 12th.
On average, analysts expect that Fennec Pharmaceuticals will report full-year earnings of ($0.59) per share for the current financial year, with EPS estimates ranging from ($0.61) to ($0.56). For the next fiscal year, analysts expect that the business will post earnings of $1.74 per share, with EPS estimates ranging from $0.08 to $3.39. Zacks’ EPS averages are a mean average based on a survey of sell-side research firms that follow Fennec Pharmaceuticals.
Fennec Pharmaceuticals (NASDAQ:FENC) last announced its earnings results on Thursday, May 9th. The company reported ($0.13) EPS for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.01.
Hedge funds have recently bought and sold shares of the company. Oxford Asset Management LLP raised its holdings in shares of Fennec Pharmaceuticals by 490.2% during the first quarter. Oxford Asset Management LLP now owns 84,750 shares of the company’s stock worth $411,000 after acquiring an additional 70,391 shares during the period. Charles Schwab Investment Management Inc. raised its holdings in shares of Fennec Pharmaceuticals by 29.0% during the first quarter. Charles Schwab Investment Management Inc. now owns 27,211 shares of the company’s stock worth $132,000 after acquiring an additional 6,111 shares during the period. Renaissance Technologies LLC acquired a new stake in shares of Fennec Pharmaceuticals during the first quarter worth $151,000. State of Wisconsin Investment Board raised its holdings in shares of Fennec Pharmaceuticals by 30.0% during the first quarter. State of Wisconsin Investment Board now owns 15,600 shares of the company’s stock worth $76,000 after acquiring an additional 3,600 shares during the period. Finally, Parametric Portfolio Associates LLC raised its holdings in shares of Fennec Pharmaceuticals by 33.3% during the first quarter. Parametric Portfolio Associates LLC now owns 42,165 shares of the company’s stock worth $205,000 after acquiring an additional 10,538 shares during the period. Institutional investors and hedge funds own 48.99% of the company’s stock.
NASDAQ:FENC traded up $0.07 during trading hours on Wednesday, reaching $4.30. 136,585 shares of the company traded hands, compared to its average volume of 58,581. The stock has a market cap of $85.55 million, a PE ratio of -8.60 and a beta of -0.33. Fennec Pharmaceuticals has a 1-year low of $3.91 and a 1-year high of $12.51.
Fennec Pharmaceuticals Company Profile
Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.
Featured Article: How to calculate the annual rate of depreciation
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Fennec Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fennec Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.